StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3036% above fair value
$461.26−4.19 (-0.90%)

Close on Nov 3, 2026Market cap $249.37BP/E 28.6Yield 2.09%

Amgen KANJINTI (trastuzumab-anns by Quarter

KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)

QuarterlyAnnual

Amgen KANJINTI (trastuzumab-anns: -33.0% in Q4 2023, up 22.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
-33.0%
Period ended Dec 31, 2023
Change on a year earlier
+22.0 pts
-55.0% in Q4 2022
History
13 quarters
Since Q4 2020
Sources
13
Documents cited below

Where the Q4 2023 figure comes from

“|| KANJINTI ® | 31 | 11 | 42 | 63 | (33%)”

Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗

Reported in Form 8-K Product Sales Detail by Product and Geographic Region.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
Q4 2023Dec 31, 2023-33.0%+22.0 ptsForm 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-72.0%-34.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023-41.0%+5.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023-51.0%-11.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-55.0%-43.0 ptsForm 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022-38.0%-7.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 2022-46.0%-73.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 2022-40.0%-75.0 ptsForm 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 2021-12.0%-65.0 ptsForm 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 2021-31.0%–Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202127.0%–Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 202135.0%–Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 202053.0%–Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗

Cite this data

StockData. (2026). Amgen KANJINTI (trastuzumab-anns (%), quarterly Q4 2020–Q4 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-kanjinti-yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?